Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130695) titled 'Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Virginia Commonwealth University
Condition:
Acute Myeloid Leukemia
Intervention:
Drug: Olutasidenib Investigational Agent Administration
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 31, 2025
Target Sample Size: 15
Countries of Recruitment:
United States
To know more, visit https://clinicaltri...